Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease

Narek A Tmoyan1, Olga I Afanasieva2, Marat V Ezhov1

  • 1A.L. Myasnikov Institute of Clinical Cardiology, National Medical Research Center of Cardiology, Ministry of Health of the Russian Federation, 121552 Moscow, Russia.

Insights

Elevated lipoprotein(a) (Lp(a)) is linked to more severe atherosclerosis across multiple arteries. As atherosclerosis progresses, Lp(a) levels rise while specific autoantibodies decrease, indicating a complex relationship.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Biochemistry

Background:

  • Lipoprotein(a) (Lp(a)) is a known genetic risk factor for coronary artery disease.
  • Limited data exists on Lp(a)'s association with atherosclerosis in other vascular beds and its overall severity.
  • This study investigates Lp(a), its autoantibodies, and inflammatory markers in relation to multi-vascular atherosclerosis.

Purpose of the Study:

  • To evaluate the association between lipoprotein(a) (Lp(a)) and atherosclerosis in coronary, carotid, and lower limb arteries.
  • To examine the relationship of Lp(a) autoantibodies and generalized inflammatory markers with the extent and severity of atherosclerosis.
  • To determine if Lp(a) is an independent risk factor for stenotic atherosclerosis across different vascular beds.

Main Methods:

  • Inclusion of 1288 adult patients with clinical and imaging assessments of three major arterial systems.
  • Categorization of patients based on the number of affected vascular beds (0, 1, 2, or 3).
  • Assessment of lipid profiles, C-reactive protein, circulating immune complexes, Lp(a), and its autoantibodies.

Main Results:

  • An increasing number of affected vascular beds correlated with higher Lp(a) levels and lower IgM autoantibodies to Lp(a).
  • Elevated Lp(a) (Hyperlipoproteinemia(a)) was more prevalent in patients with atherosclerosis.
  • Logistic regression confirmed elevated Lp(a) as independently associated with stenotic atherosclerosis and lesion severity, adjusted for major cardiovascular risk factors.

Conclusions:

  • Lipoprotein(a) (Lp(a)), C-reactive protein, circulating immune complexes, and neutrophil-to-lymphocyte ratio are associated with stenotic atherosclerosis in multiple vascular beds.
  • Lp(a) levels increase, while IgM autoantibodies to Lp(a) decrease, with a greater number of affected vascular beds.
  • These findings highlight Lp(a) as a significant factor in the development and severity of atherosclerosis across the arterial tree.
Abstract

Related Concept Videos

Inflammation01:38

Inflammation

Overview
57.8K
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
366
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
150
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
114
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
185
Lipid-derived Compounds in the Human Body01:31

Lipid-derived Compounds in the Human Body

Fats and lipids are crucial components in the human body. Some lipid-derived compounds, such as fat-soluble vitamins, eicosanoids, lipoproteins, and glycolipids, also play unique roles to support various  biological processes .
Fat-soluble Vitamins
Fat-soluble vitamins, including vitamins A, D, E, and K, are required in minimal quantities, but their deficiencies can lead to severely abnormal physiological conditions. For example, vitamin A deficiency can cause night blindness, dry skin,...
5.8K